Myxedema coma, a rare life-threatening complication of hypothyroidism, is a loss of brain function. This extreme manifestation of hypothyroidism is an infrequent but potentially fatal condition. Women are four times more prone to suffer from hypothyroidism compared to men and correspondingly 80 percent incidences of myxedema coma occur in females. If seasonality is to be considered above 90% cases happen in winters. This seasonal prevalence could be apparently because of inability to sense temperature and lower body heat production in the elderly, secondary to hypothyroidism. Major symptoms of myxedema coma include abnormal low body temperature (sometimes as low as 80 degrees F), severe mental conditions (like hallucinations, seizers, disorientation), edema with swollen eyes, hair loss, difficulty in breathing among many more. The best of treating myxedema coma is preventing it in the first place. The factors which could trigger myxedema coma are certain types of drugs, heart stroke, gastrointestinal bleeding, trauma, infections, and not taking prescribed thyroid medications.
The ongoing COVID-19 pandemic has taken all the focus of researchers and industry players which has resulted in pushing back of already less researched niche domains like myxedema coma. Additionally, the financial demands of rare diseases like myxedema coma are unmet due to persion of funds towards more pressing needs experienced due to COVID-19.
Myxedema Coma Market: Drivers and Restraints
In case of myxedema coma, the family physicians are in an important position to prevent the condition by maintaining a high level of suspicion for hypothyroidism during the regular follow up visits. Hence growing awareness among people to pay regular visit to doctors will be a key driver for the growth of myxedema coma market. Another reason which could drive the global myxedema coma treatment market is high mortality rate in the patients which is reported up to 60%. The pharmaceutical moguls would like to bring down this rate substantially. The developed countries are witnessing change in demographics, their population is ageing. Myxedema coma being a disorder affecting the elderly hence will drive the global market for myxedema coma. The symptoms of hypothyroidism are often subtle and go unnoticeable which will consequently result in hindering the market for myxedema coma.
Myxedema Coma Market: Segmentation
The international myxedema coma treatment market is segmented based on indication type, drug class, route of administration and distribution channel.
By indication type, the global myxedema coma market is segmented as:
By drug class, the global myxedema coma market is segmented as:
By route of administration, the global myxedema coma market is segmented as:
By distribution channel, the global myxedema coma market is segmented as:
Myxedema Coma Market: Overview
With the estimated cases at 1.08 cases per million and total cases at approximately 7000 cases per year worldwide per year, the overall myxedema coma treatment market is expected to record a steady growth. By drug class, the natural origin segment in the global myxedema coma market is expected to witness a robust growth based on patient preferences. By route of administration, oral segment in the global myxedema coma market is estimated to grow faster than the injectable segment owing to patient convenience. By distribution channel, retail pharmacies in the global myxedema coma market are estimated to register a sound growth.
Myxedema Coma Market: Region-wise Outlook
North America is expected to occupy major chunk of the global myxedema coma market as the incidences of hypothyroidism are expected to increase in coming years. Europe will be the next major market in the global myxedema coma market owing to the fact that significant population suffers from hypothyroidism coupled with various conditions like heart failure, stroke which are the precipitating factors for myxedema coma. Numerous regions in Asia, Africa and Latin America can be estimated as emergent market for myxedema coma treatment as these areas suffer from iodine deficiency which is a leading cause of hypothyroidism.
Myxedema Coma Market: Key Players
The key players for the global myxedema coma market are Lupin, Par Pharmaceutical, Merck & Co., Amneal Pharmaceuticals, Abbott Laboratories, IBSA Pharma Inc, Pfizer, Alara Pharmaceutical, RLC Labs, Acella Pharmaceuticals among others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on:
Regional analysis includes:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.